Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Preliminary liquidity of approximately $128.7 million in cash, equivalents and marketable securities as of September 30, 2026.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary liquidity of approximately $128.7 million in cash, equivalents and marketable securities as of September 30, 2026
- Financial close and review remain ongoing, creating potential for the liquidity figure to change
- Updated investor presentation provides the disclosure, while full quarterly financial results remain pending
Item 8.01 · Other Events
- Completed rolling BLA submission to FDA for accelerated approval of nomlabofusp in Friedreich’s ataxia
- Regulatory milestone potentially advances nomlabofusp toward FDA review and commercialization
- Updated corporate presentation signals refreshed investor messaging and program data availability
Item EX-99.1 · Exhibit EX-99.1
- Completed rolling BLA submission for nomlabofusp, seeking accelerated approval for Friedreich’s ataxia
- FDA willing to consider skin frataxin as a novel surrogate endpoint, but acceptance and approval remain uncertain
- Open-label data showed sustained skin frataxin increases and directional clinical improvements versus natural-history references
- Key catalysts: BLA acceptance early 2027, approval targeted mid-2027, U.S. launch targeted Q3 2027 if approved
- FORWARD-FA Phase 3 enrollment underway, testing daily treatment over 18 months in participants ages 2 to 40
Item EX-99.2 · Exhibit EX-99.2
- Completed rolling BLA submission in November 2026, seeking accelerated approval using skin FXN as a novel surrogate endpoint
- FDA acceptance targeted for early 2027, with potential U.S. approval mid-2027 and launch in Q3 2027
- Open-label data showed sustained skin FXN increases, reaching asymptomatic-carrier range in 100% of evaluable participants at 1 year and 18 months
- Clinical evidence remains directional, with a 2.6-point mFARS advantage versus FACOMS at 1 year and 4.6 points at 18 months
- $128.7 million cash and investments as of September 30, 2026, projected runway into late Q2 2027, creating financing risk before potential approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.